港股创新药板块延续调整，资金逆势加仓，恒生创新药ETF（159316）盘中获2200万份净申购

Core Viewpoint - The Hong Kong innovative drug sector continues to experience a pullback, with the Hang Seng Innovative Drug Index down by 3.5% as of 13:40, despite significant capital inflow into related products, indicating a mixed market sentiment towards innovative pharmaceuticals [1] Group 1: Market Performance - The Hang Seng Innovative Drug ETF (159316) saw a net subscription of 22 million units during intraday trading, following two consecutive days of net inflow, bringing its latest scale to 1.7 billion yuan, a record high [1] - The recent adjustment of the Hang Seng Innovative Drug Index, which now excludes contract research organizations (CROs), has resulted in a more accurate reflection of the performance of domestic innovative drug companies [1] Group 2: Upcoming Events and Trends - The World Lung Cancer Conference (WCLC) and the European Society for Medical Oncology (ESMO) annual meeting are scheduled for September and October 2025, respectively, where several domestic innovative drugs, such as Akeso's AK112 and InnoCare's DB-1311, will showcase their research results [1] - The competitiveness of domestic innovative drugs in clinical data and progress is increasing globally, leading to a growing trend of innovative drugs entering international markets [1] Group 3: Index Performance - The removal of CROs from the index has led to higher annualized returns and Sharpe ratios since the index's launch on July 10, 2023, indicating improved performance metrics for the remaining innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this newly adjusted index, providing investors with a targeted opportunity to capitalize on the growth of the innovative drug sector [1]